Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 10;11(5):e043488.
doi: 10.1136/bmjopen-2020-043488.

Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke

John-Paul Nicolo  1   2   3   4 , Zhibin Chen  3   4 , Bradford Moffat  5 , David K Wright  3 , Benjamin Sinclair  3 , Rebecca Glarin  5 , Andrew Neal  6   2   3   4 , Vincent Thijs  7   8 , Udaya Seneviratne  9   10 , Bernard Yan  2   4 , Geoffrey Cloud  6   3 , Terence J O'Brien  6   2   3   4 , Patrick Kwan  6   2   3   4
Affiliations

Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke

John-Paul Nicolo et al. BMJ Open. .

Abstract

Introduction: Stroke is a common cause of epilepsy that may be mediated via glutamate dysregulation. There is currently no evidence to support the use of antiseizure medications as primary prevention against poststroke epilepsy. Perampanel has a unique antiglutamatergic mechanism of action and may have antiepileptogenic properties. This study aims to evaluate the efficacy and safety of perampanel as an antiepileptogenic treatment in patients at high risk of poststroke epilepsy.

Methods and analysis: Up to 328 patients with cortical ischaemic stroke or lobar haemorrhage will be enrolled, and receive their first treatment within 7 days of stroke onset. Patients will be randomised (1:1) to receive perampanel (titrated to 6 mg daily over 4 weeks) or matching placebo, stratified by stroke subtype (ischaemic or haemorrhagic). Treatment will be continued for 12 weeks after titration. 7T MRI will be performed at baseline for quantification of cerebral glutamate by magnetic resonance spectroscopy and glutamate chemical exchange saturation transfer imaging. Blood will be collected for measurement of plasma glutamate levels. Participants will be followed up for 52 weeks after randomisation.The primary study outcome will be the proportion of participants in each group free of late (more than 7 days after stroke onset) poststroke seizures by the end of the 12-month study period, analysed by Fisher's exact test. Secondary outcomes will include time to first seizure, time to treatment withdrawal and 3-month modified Rankin Scale score. Quality of life, cognitive function, mood and adverse events will be assessed by standardised questionnaires. Exploratory outcomes will include correlation between cerebral and plasma glutamate concentration and stroke and seizure outcomes.

Ethics and dissemination: This study was approved by the Alfred Health Human Research Ethics Committee (HREC No 44366, Reference 287/18).

Trial registration number: ACTRN12618001984280; Pre-results.

Keywords: epilepsy; magnetic resonance imaging; stroke medicine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

See all similar articles

Cited by

References

    1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993;34:453–8. 10.1111/j.1528-1157.1993.tb02586.x - DOI - PubMed
    1. Beghi E, Carpio A, Forsgren L, et al. . Recommendation for a definition of acute symptomatic seizure. Epilepsia 2010;51:671–5. 10.1111/j.1528-1167.2009.02285.x - DOI - PubMed
    1. Fisher RS, Acevedo C, Arzimanoglou A, et al. . ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55:475–82. 10.1111/epi.12550 - DOI - PubMed
    1. Arntz RM, Maaijwee NAM, Rutten-Jacobs LCA, et al. . Epilepsy after TIA or stroke in young patients impairs long-term functional outcome: the future study. Neurology 2013;81:1907–13. 10.1212/01.wnl.0000436619.25532.f3 - DOI - PubMed
    1. Koome M, Churilov L, Chen Z, et al. . Computed tomography perfusion as a diagnostic tool for seizures after ischemic stroke. Neuroradiology 2016;58:577–84. 10.1007/s00234-016-1670-5 - DOI - PubMed

Publication types

LinkOut - more resources